Phase I EffTox Study of Aurora A Kinase Inhibitor Alisertib (MLN8237) Given in Combination With Selective VEGFR Inhibitor Pazopanib (Votrient) for Therapy of Solid Tumors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 07 Nov 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Alisertib (Primary) ; Pazopanib (Primary)
Indications Advanced breast cancer; Colon cancer; Head and neck cancer; Lung cancer; Pancreatic cancer; Renal cancer; Sarcoma; Solid tumours
Focus Adverse reactions

18 Apr 2017 Status changed from active, no longer recruiting to completed.
18 Nov 2016 Planned End Date changed from 1 Sep 2016 to 1 Mar 2017.
18 Nov 2016 Planned primary completion date changed from 1 May 2016 to 1 Mar 2017.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com